Arthneeti

Shukra Pharmaceuticals Share Price & Earnings Call Analysis

₹79.85-0.06% today
Market cap
₹3,534 Cr
P/E
98.05
ROE
28.88%
PEG
1.38
Price to sales
47.22
Debt to equity
0.06
52W high / low
₹79.9 / ₹27.2
Sales growth (5Y)
38.37%
EBITDA margin
64.97%
Net profit margin
38.88%
Promoter holding
51.16%
Sales (last year)
₹75 Cr

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Shukra Pharmaceuticals rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Shukra Pharmaceuticals.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Shukra Pharmaceuticals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Shukra Pharmaceuticals

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +46.2520.1624.6418.8910.883.185.5610.5813.275.395.8839.136.30
Expenses +42.6019.8219.559.346.452.384.906.655.964.076.2912.005.61
Operating Profit3.650.345.099.554.430.800.663.937.311.32-0.4127.130.69
OPM %7.89%1.69%20.66%50.56%40.72%25.16%11.87%37.15%55.09%24.49%-6.97%69.33%10.95%
Other Income +0.890.630.240.561.380.721.021.011.471.111.710.820.95
Interest0.070.080.060.070.070.060.110.150.270.270.290.280.26
Depreciation0.510.460.560.510.520.670.700.700.940.790.810.841.01
Profit before tax3.960.434.719.535.220.790.874.097.571.370.2026.830.37
Tax %-0.25%2.33%-0.21%1.05%23.75%40.51%39.08%22.74%28.80%25.55%-1,090.00%24.08%567.57%
Net Profit +3.980.424.719.423.990.490.543.165.391.032.3820.36-1.73
EPS in Rs0.090.010.110.220.090.010.010.070.120.020.050.46-0.04

Financials of Shukra Pharmaceuticals

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3555612112059753357
Expenses +3444410101853552028
Operating Profit-011222135191329
OPM %-10%24%28%30%29%13%13%14%9%26%39%51%
Other Income +1-00000001345
Interest000000000011
Depreciation100111122233
Profit before tax001110014201329
Tax %52%66%52%45%37%82%-90%26%1%7%28%23%
Net Profit +000100014191022
EPS in Rs0.000.000.010.010.010.000.000.020.100.420.220.50
Dividend Payout %0%0%16%15%17%0%0%10%4%6%5%0%

Financials of Shukra Pharmaceuticals

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital222222224114444
Reserves121313131414141521471946
Borrowings +1004681035345
Other Liabilities +3346710101545172023
Total Liabilities1817192428343635757887117
Fixed Assets +101010141617181820201922
CWIP2222222222212
Investments000000000000
Other Assets +76781114161653566584
Total Assets1817192428343635757887117

Financials of Shukra Pharmaceuticals

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-23-0101183-583
Cash from Investing Activity +1-0-1-5-2-3-2-2-4-1-1-14
Cash from Financing Activity +1-103222-7512-55
Net Cash Flow01-1-00-00-0462-6
Free Cash Flow-12-1-4-2-2-16-1-75-13
CFO/OP812%237%7%63%25%81%38%292%64%-24%92%17%

Financials of Shukra Pharmaceuticals

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days737117520034524531813218712098148
Inventory Days55492112531001692211392519447320
Days Payable2911084007341,16178670230327159414232
Cash Conversion Cycle33554-112-480-717-372-163-32-5880131236
Working Capital Days7582583443794402262785741157404352
ROCE %-1%6%7%6%4%0%1%6%19%44%22%37%
97out of 100

Momentum score · price trend

97 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+94.8%93%
Last 6 months+162.0%99%
Last 3 months+164.3%100%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Shukra Pharmaceuticals: 0.4 × 93 + 0.4 × 99 + 0.2 × 100 = 97.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals